A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
18 Years
55 Years
Both
Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
Trial Information
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
The treatment protocol consisted of monthly 12 mg/m2 MITO intravenous infusions for 6 months
followed by 3 additional treatments every 3 months. Neurological assessment including the
determination of the Expanded Disability Status Scale (EDSS) score was performed every 3
months and during relapses. Orbital, brain and spinal cord MRI was performed at baseline,
3, 6, 12, 18, and 24 months. Visual evoked potentials and ophthalmologic evaluations were
performed at baseline and annually.
Inclusion Criteria:
- Recurrent longitudinal myelitis (>3 segments of spinal cord involvement by MRI) with
or without recurrent ON (unilateral or bilateral) but with normal brain MRI.
- Patients with recurrent longitudinally extensive myelitis without optic neuritis have
an underlying pathology and serology similar to NMO and it is appropriate to consider
this a form of NMO10.
- Cerebrospinal fluid required no intrathecal IgG synthesis or oligoclonal bands.
- Age was required to be 18-55 years
- Extended Disability Status Score ≤ 7.
Exclusion Criteria:
- Cardiac risk factors (e.g history of congestive heart failure and left ventricular
ejection fraction (LVEF) < 50%
- Systemic diseases such as lupus, Sjogren’s syndrome, anti-phospholipid antibody
syndrome, sarcoidosis, rheumatoid arthritis, or vitamin B12 deficiency
- Previous treatment with mitoxantrone or anthracyclines
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Relapse rate
Principal Investigator
Bianca Weinstock-Guttman, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
Baird Multiple Sclerosis Center
Authority:
United States: Food and Drug Administration
Study ID:
JNI-NMO-101
NCT ID:
NCT00304291
Start Date:
August 2001
Completion Date:
May 2004
Related Keywords:
- Neuromyelitis Optica
- Myelitis, Transverse
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Novantrone
- Autoimmune Diseases
- Myelitis
- Myelitis, Transverse
- Nervous System Diseases
- Neuromyelitis Optica
- Autoimmune Diseases of the Nervous System
- Demyelinating Autoimmune Diseases, CNS
Name | Location |
|---|---|
| Baird Multiple Sclerosis Center | Buffalo, New York 14203 |
